Phase 2: low-dose Regorafenib: Clinical Trials

1 unknown. 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	1	Unknown 1
Phase 2	1	Unknown 1

Follow Phase 2: low-dose Regorafenib: new trials by email Literature Review of Phase 2: low-dose Regorafenib trials Research Report on Phase 2: low-dose Regorafenib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST	Phase 1 / Phase 2	Unknown	Institut Bergonié	747	2018-05-04	2023-03-03

Conditions studied

Biliary Tract Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)  ·  Mesothelioma, Malignant (1)  ·  Neoplasm Metastasis (1)  ·  Sarcoma (1)  ·  Stomach Neoplasms (1)  ·  Tertiary Lymphoid Structures (1)  ·  Thyroid Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Turcot syndrome (1)

Sponsors

Institut Bergonié (1)

Countries

France (1)

Results publications

PMID 34965951, PMID 34998048, PMID 40204996, PMID 40579407

NIH funding

2016 (1)